Yi-Min Zheng

2PUBLICATIONS
6CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (2)

|Jun 02, 2025
The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC.

Bu-Gang Liang, Yi-Min Zheng, Ming-Hao Xu

|Feb 26, 2025
Cordycepin mediates pyroptosis in HCC through the upregulation of TXNIP and synergizes with anti-PD-L1 immunotherapy.

Bu-Gang Liang, Yi-Min Zheng, Hong-Ye Shen

Pageof 1